Biotech Rallies in Hong Kong as BD Deals Accelerate
On April 1, the Hang Seng Biotech Index surged 6.78% in a single day, followed by another 0.89% gain on April 2, closing at 15,641. From the ETF side, funds tracking healthcare and biotech moved higher in sync with the index. $CAM HSBIOTECH(03069)$ rose 0.58%, $CSOP HSBIOTECH(03174)$ gained 0.92%, and $GX CN BIOTECH(02820)$ increased 1.17%, showing a consistent upward trend alongside the broader sector. Capital allocation into passive products is also picking up. At the stock level, $HANSOH PHARMA(03692)$ rose 5.18%, $INNOCARE(09969)$ gained 4.44%,
China Resources Pharmaceutical Group Ltd is an investment holding company principally engaged in the pharmaceutical business. The Company operates its business through four segments. The Pharmaceutical Business segment develops, manufactures and sells a range of pharmaceuticals and health products. The Pharmaceutical Distribution Business segment provides distribution, warehousing, logistics and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers, device manufacturer and dispensers, including hospitals, distributors and retail pharmacies. The Pharmaceutical Retail Business segment operates retail pharmacies. The Other Business Operations segment engages in property holding and other businesses.